Liraglutide vs Setmelanotide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Liraglutide

Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.

Full details →

Setmelanotide

Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).

Full details →

Side-by-Side Comparison

AspectLiraglutideSetmelanotide
MechanismBinds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects.Selective agonist of melanocortin 4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes.
Typical DosageSaxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily.Adults: Start 2mg daily, titrate based on tolerability up to 3mg daily. Pediatrics (6+): Weight-based dosing starting at 1mg daily.
AdministrationSubcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications.Subcutaneous injection once daily. Requires genetic testing to confirm eligible mutations before prescribing.
Side EffectsNausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use.Injection site reactions, skin hyperpigmentation, spontaneous penile erections, depression, and suicidal ideation (boxed warning). GI effects less common than GLP-1s.
Best For

What They Have in Common

Both Liraglutide and Setmelanotide are commonly used for:

Ready to Learn More?